In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, CRH Medical (TSX: CRH). Analyst Douglas Miehm from RBC Capital reiterated a Buy rating, with a C$5.50 price target today.
According to TipRanks.com, Miehm has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.3% and a 43.2% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Novelion Therapeutics Inc, and Shire.
Read also: INSYS Therapeutics (INSY) Stock Fires on All Cylinders; Here’s Why
CRH Medical has an analyst consensus of Strong Buy, with a price target consensus of C$5.67, representing a 3.5% upside. In a report issued on August 21, National Bank also maintained a Buy rating on the stock with a C$5.75 price target.
.
The company has a one-year high of C$5.57 and a one-year low of C$1.86. Currently, CRH Medical has an average volume of 164.8K.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Wednesday at C$5.48, close to its 52-week high of C$5.57.
